anti-Spike IgG – Page 11 – Communicable Diseases Research

Case-Control Study of Individuals with Discrepant Nucleocapsid and Spike Protein SARS-CoV-2 IgG Results

뉴클레오캡시드 및 스파이크 단백질 SARS-CoV-2 IgG 결과가 일치하지 않는 개인에 대한 사례 대조 연구

Article

Published on 2021-07-062022-09-11
Journal: Clinical Chemistry [Category] SARS, 진단, 치료기술, 치료법, 치료제,

Low Innate Immunity and Lagged Adaptive Immune Response in the Re-Tested Viral RNA Positivity of a COVID-19 Patient

COVID-19 환자의 재검사된 바이러스 RNA 양성에서 낮은 선천성 면역 및 지연된 적응 면역 반응

Immunology

Published on 2021-07-012022-09-11
Journal: Frontiers in Immunology [Category] SARS, 유전자 메커니즘, 진단, 치료법,

[키워드] accompanied Adaptive immune response analyzed anti-RBD anti-RBD IgA anti-SARS-CoV-2 antibody anti-Spike IgG antibody Antigen Antigen presentation B cell CD8+ Cell Characteristics chemokine chemokines Chest computed tomography Computed tomography contributed COVID-19 COVID-19 patient COVID-19 patients cytokine Cytokines delayed anti-RBD/anti-spike IgA conversion delayed antigen presentation delayed neutralizing antibody response described disappearance discharged domain expression Gene Expression IgA IgG immune mechanism Innate interferon low expression lung lesion lung lesions Mild-to-moderate moderate moderate symptoms NAb NAbs Neutralizing antibodies neutralizing antibody observation observations Patient plasma positive RBD RBD IgA re-tested positivity recent reported response RNA SARS-CoV-2 SARS-CoV-2 RNA Seroconversion severe patients significantly Symptom Symptoms T cells T cells- the SARS-CoV-2 titer Viral Viral RNA Whole blood
[DOI] 10.3389/fimmu.2021.664619 PMC 바로가기 [Article Type] Immunology

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

HIV 감염에서 SARS-COV-2에 대한 Chadox1 NCOV-19 (AZD1222) 백신의 안전성 및 면역 원성 : 2/3 상 임상 시험의 단일 암 보체.

Clinical Trial

Published on 2021-06-182022-08-13
Journal: The Lancet. HIV [Category] MERS, SARS, 임상, 진단,

[키워드] ACHE age All participants analysed analyses anti-Spike IgG anti-spike IgG response Anti-spike IgG responses antibody Antiretroviral therapy ART AstraZeneca available data AZD1222 CD4 CD4 cell CD4 count CD4 counts Cell cell-mediated immune response Cell-mediated immune responses cellular response Cellular responses ChAdOx1 ChAdOx1 nCoV-19 chill chills Clinical research clinical trial Coalition Comorbidity determined by dose Eligible participants ELISA ELISPOT enrolled enrolment enzyme enzyme-linked immunospot assay fatigue finding FIVE frequencies Frequency functional funding General population headache HIV HIV clinics HIV-negative HIV-uninfected humoral Humoral response humoral responses IFN-γ IgG response IgG responses immune responses Immunity immunogenic immunogenicity injection injection site Innovation IQR joint joint pain less Live virus Local London magnitude malaise male median median age muscle ache nausea network neutralisation NIHR NIHR Oxford Biomedical Research Centre no correlation no difference occurred Open-label outcome Oxford Pain participant Participants peaked people with HIV persistence phase 2/3 phase 2/3 trial plasma Primary outcome Primary outcomes prime-boost regimen proliferation proliferative protocol reactogenicity Registered reported required response Safe Safety SARS-CoV-2 SARS-CoV-2 spike-specific Serious Adverse Event Serious Adverse Events single-arm South sustained systemic reaction systemic reactions T-cell the vaccine undetectable vaccination Vaccine vaccine immunogenicity Valley Viral Viral load were measured with HIV
[DOI] 10.1016/S2352-3018(21)00103-X PMC 바로가기 [Article Type] Clinical Trial

Young infants exhibit robust functional antibody responses and restrained IFN-γ production to SARS-CoV-2

어린 유아는 SARS-CoV-2에 대한 강력한 기능적 항체 반응과 억제된 IFN-γ 생산을 나타냅니다.

Comparative Study

Published on 2021-06-092022-09-12
Journal: Cell Reports Medicine [Category] MERS, 진단,

High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages

초기 인간 항-SARS-CoV-2 IgG의 높은 역가 및 낮은 푸코실화는 폐포 대식세포에 의한 염증을 촉진합니다

Research Article

Published on 2021-05-112022-09-12
Journal: Science Translational Medicine [Category] MERS, SARS, 임상, 진단,

[키워드] Activation acute respiratory distress acute respiratory distress syndrome Adaptive immune response addition alveolar alveolar macrophage Alveolar macrophages anti-SARS-CoV-2 IgG Anti-spike anti-Spike IgG anti-spike protein IgG antibody coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient Critically ill critically ill COVID-19 patients cytokine Cytokines dependent on diagnosed disease driven by early phase Evidence excessive inflammatory response Fcγ receptor FcγR FDA feature fostamatinib glycosylation hallmark human macrophage IgG IIa in vitro induce infection with SARS-CoV-2 Inflammation Inflammatory response inhibitor initial interleukin interleukin-6 intrinsically Macrophage macrophage activation macrophages Microvascular thrombosis Necrosis occur Patient pro-inflammatory promote promote inflammation pulmonary endothelial receptor respiratory distress Respiratory distress syndrome responsible SARS-CoV-2 second Seroconversion serum severe COVID-19 severe disease small molecule Spike protein syndrome therapeutic thrombosis Tumor tumor necrosis tumor necrosis factor was normalized worsening
[DOI] 10.1126/scitranslmed.abf8654 PMC 바로가기 [Article Type] Research Article

IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals

SARS-CoV-2에 대한 IL-33 발현은 COVID-19 회복기 개인의 혈청 양성과 상관관계가 있습니다

Article

Published on 2021-04-092022-09-12
Journal: Nature Communications [Category] MERS, SARS, 임상, 진단, 치료기술, 치료법,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adults age anti-SARS-CoV-2 antibody anti-Spike IgG Antibody titer Asthma BALF Bronchoalveolar lavage fluid CD14 CD4 Cell cells chronic disease Chronic diseases Cohort convalescent convalescent individual convalescent individuals COPD coronavirus COVID-19 COVID-19 pathogenesis days post-infection disease severity Effect elicit Epidemiology expression Fever glycoprotein IFNA2 IL-1β IL-23 IL-33 IL-6 immune immune response immune responses Immunity increase Infection Interleukins Mild Monocytes observational study Pathogenesis Patient PBMC PBMCs PCR peptide produced Pulmonary infection recall reveal SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike glycoprotein scRNAseq seronegative seropositive seropositive individuals Seropositivity Seropositivity for SARS-CoV-2 Seroprevalence severe acute respiratory syndrome Coronavirus severe COVID-19 spike spike glycoprotein spike IgG subject subset Symptoms T cell T cell activation the disease their family member their family members TLR7 TNF virus
[DOI] 10.1038/s41467-021-22449-w PMC 바로가기 [Article Type] Article

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

의료 종사자에서 SARS-CoV-2 감염의 항체 상태 및 발생률

Article

Published on 2021-02-112022-09-11
Journal: The New England Journal of Medicine [Category] MERS, SARS, 진단, 치료법,

[키워드] 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted age anti-Nucleocapsid IgG Anti-spike anti-spike antibodies anti-Spike IgG antibody antibody status assays Asymptomatic baseline baseline antibody status Chain Reaction changes in Combination coronavirus Department determine determined by Follow-up Gender Health care Health care worker incidence incidence rate investigated occurred Oxford participated PCR PCR-positive polymerase chain polymerase chain reaction positive positive PCR test presence of antibody primary analysis rate ratio rate ratios reduced risk Reinfection respiratory risk SARS-CoV-2 SARS-COV-2 infection Seroconversion seronegative seropositive severe acute respiratory syndrome Coronavirus status subsequent symptomatic symptomatic infection symptomatic infections test results tested United Kingdom university was determined was used worker
[DOI] 10.1056/NEJMoa2034545 PMC 바로가기 [Article Type] Article

A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity

SARS-CoV-2 감염 환자에 대한 종단 연구는 중화 항체와 COVID-19 중증도 사이에 높은 상관관계가 있음을 보여줍니다

Article

Published on 2021-01-062022-09-11
Journal: Cellular and Molecular Immunology [Category] Fulltext, MERS, 변종, 진단,

[키워드] absence anti-Spike IgG anti-spike IgG levels antibody Asymptomatic Cohort contribute coronavirus correlated strongly COVID-19 COVID-19 severity Critical cross-neutralization D614G mutation disease disease severity disease symptom elicited Endemic Europe exhibited forms generate had no Health policy heterogeneous high correlation human coronavirus human coronaviruses humoral Humoral response immune correlate immune correlates immune response immune responses individual Infection infections intensive care intensive care unit intensive care units live SARS-CoV-2 Mild symptom mild symptoms NAb NAb activity NAb titers NAbs neutralization neutralizing antibody other coronaviruses Particle Pathogenesis pathogenesis of SARS-CoV-2 Patient Prognostic markers Protective Protein pseudotyped public health qPCR Reinfection required retroviruses reveal SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-infected patient SARS-CoV-2-infected patients serum sample serum samples spike Spike protein the SARS-CoV-2 the spike protein understanding Vaccine development variant Viral viral infection viral surface
[DOI] 10.1038/s41423-020-00588-2 PMC 바로가기 [Article Type] Article

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Clinical Trial

Published on 2020-09-022022-10-04
Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 임상, 진단,

[키워드] acute respiratory syndrome addition Adults adverse event adverse events anti-Spike IgG Antigen assigned CD4+ T-cell Coalition composed convalescent serum coronavirus cytokine doses drug elicited ELISA enzyme-linked immunosorbent evaluate exceeded Fever food full-length SARS-CoV-2 geometric healthy IgG immune response immune responses initiated intramuscular injections Laboratory majority Matrix-M1 adjuvant microneutralization Mild nanoparticle neutralization NVX-CoV2373 outcome participant Participants Patient performed phase Placebo placebo-controlled primary analysis Primary outcome Protein randomization Randomized receive recombinant regimen response Result Safe SARS-CoV-2 secondary Serious Adverse Event serum chemistry severe adverse events short duration spike spike glycoprotein staining symptomatic symptomatic COVID-19 T helper T-cell Response Th1 Th1 phenotype the vaccine Toxicity Trial trimeric vaccination Vaccine wild-type virus
[DOI] 10.1056/NEJMoa2026920 PMC 바로가기 [Article Type] Clinical Trial